Nivolumab Plus Ipilimumab Proven Cost Effective in Advanced RCC
An analysis of the immunotherapy combination compared with sunitinib placed the combo on the high end of willingness-to-pay thresholds for cancer drugs.
Urology News
UROLOGY NEWS
Long-Term PCa Treatment Outcomes Superior With Radiation Plus ADT
Updated findings from a phase 3 study show significantly better 8-year progression-free survival with external beam radiation therapy added to androgen deprivation therapy (ADT) vs ADT alone.
Prostate mpMRI May Be Helpful in the Neoadjuvant PCa Therapy Setting
Prostate mpMRI findings before and after neoadjuvant therapy prior to robotic prostatectomy could be useful in assessing whether high-risk patients are suitable surgical candidates.
Morbidity Low With Focal Laser Ablation of Prostate Cancer
Tumor diameter above the median was only significant predictor for positive MRI after treatment
FDA: Patients Should Not Abruptly Stop Taking a Prescribed Opioid
Agency warns that rapid discontinuation can result in uncontrolled pain or withdrawal symptoms
Agent Orange Possibly Protective in Prostate Cancer ADT Recipients
New study finds that Vietnam War exposure to the defoliant Agent Orange is associated with a reduced death risk among men receiving androgen deprivation therapy for advanced prostate cancer.
Preventive Drugs Often Used in Last Year of a Cancer Patient’s Life
Preventive drugs, including antihypertensives and statins, frequently continued until final month of life
Investigational Oral Carbapenem Antibiotic Gets Fast-Tracked for cUTI, Acute Pyelonephritis
Spero Therapeutics announced that the Food and Drug Administration (FDA) has granted Fast Track designation for SPR994 (tebipenem pivoxil hydrobromide) for the treatment of complicated urinary tract infections (cUTI) and acute pyelonephritis (AP)
Standard of Care for mRCC May Change
Data support first-line treatment with combined regimens that include an immunotherapeutic agent
Biparametric MRI May Suffice for Prostate Cancer Detection
Biparametric MRI detects prostate tumors with an accuracy similar to that of multiparametric MRI without the cost and risks associated with intravenous gadolinium contrast, a new meta-analysis suggests.
Want to read more?
Please login or register first to view this content.
Next post in Kidney Cancer
